4th Opdivo indication
March 21, 2016
PATIENTS with advanced
non squamous non-small cell
lung cancer (NSCLC) who have
progressed on, or following prior
chemotherapy, can now access
Bristol-Myers Squibb’s (BMS)
Opdivo (nivolumab) subsequent
to the Therapeutic Goods
Administration granting approval
for this indication.
From 01 March, BMS will provide
access to Opdivo, at no cost, for
eligible patients through a Patient
Access Program (PAP) to provide
access in the period between
regulatory approval and anticipated
PBS reimbursement, although free
supply will not be open ended, the
company said.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Mar 16